Frontiers4h
Expanding the frontiers of targeting the biology of aerodigestive squamous cell cancers
Progress in targeted signaling inhibition and immunotherapy has spurred a race to transform treatment across virtually all cancer disease sites. There is ample preclinical data pointing toward the ...
GSK reports preliminary data for AREXVY
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...
Monthly Prescribing Reference16h
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...
GSK reports positive data for RSV shot in younger, at-risk adults
GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...